secwatch.observer — SEC 8-K summary
======================================

Issuer:     Catheter Precision, Inc. (VTAK)
CIK:        0001716621
Form:       8-K
Filed at:   2023-12-22T23:59:59+00:00
Accession:  0001654954-23-015944
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catheter Precision reports nine-month revenue of $314K; cash at $5.6M
---------------------------------------------------------------------

- Nine-month revenue $314K; total assets $32.9M; cash $5.6M as of Sep 30, 2023.
- Received first approval in France; VIVO now active in six European countries.
- Completed enrollment of Phase I LockeT study (>100 patients); IRB approval for Phase II randomized study.
- Initiated design changes to LockeT based on feedback; new build processes for VIVO to reduce costs.
- Acting CEO David Jenkins expects hospital approvals and purchase orders in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/0001654954-23-015944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716621/000165495423015944/rmed_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-015944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer